Abstract: A method of opioid replacement is described which involves modulating the expression of dopaminergic genes (such as DRD2), as indicative of substance use disorders in individuals utilizing opioids and desirous of opioid replacement. Opioid replacement can involve a decrease in opioid seeking behavior of the subject, who may require pain management. A cannabinoid formulation is described comprising primarily cannabichromene (CBC) together with an excipient. A method is described for detecting the correlation between CBC treatment and downregulation of biomarkers of DRD2 gene expression. An effective non-psychoactive pain management therapy for opioid replacement is provided, as validated based on the gene expression profile of patients, where patient response to cannabichromene treatment can be predicted by such biomarkers.

Abstract: A formulation for pain management is provided comprising cannabichromene as the primary cannabinoid together with an excipient and, optionally, one or more secondary cannabinoids in an amount of up to 5% by weight of the primary cannabinoid. The formulation is essentially free of tetrahydrocannabinol. The types of pain to be managed with the formulation include but are not limited to the treatment of neuropathic pain, pain due to cancer, injury, accident, surgery, or tissue damage. Methods of use of the formulation, doses and dosage forms are described.

Abstract: A formulation for pain management is provided comprising cannabichromene as the primary cannabinoid together with an excipient and, optionally, one or more secondary cannabinoids in an amount of up to 5% by weight of the primary cannabinoid. The formulation is essentially free of tetrahydrocannabinol. The types of pain to be managed with the formulation include but are not limited to the treatment of neuropathic pain, pain due to cancer, injury, accident, surgery, or tissue damage. Methods of use of the formulation, doses and dosage forms are described.